Have a personal or library account? Click to login
Amplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11 Cover

Amplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11

Open Access
|Dec 2011

References

  1. Albertson D G. Gene amplification in cancer. Trends Genet. 2006; 22(8): 447-455.10.1016/j.tig.2006.06.00716787682
  2. Gajduskova P, Snijders AM, Kwek S, Roydasgupta R, Fridlyand J, Tokuyasu T, Pinkel D, Albertson DG. Genome position and gene amplification. Genome Biol. 2007; 8(6): R120.1-16.10.1186/gb-2007-8-6-r120239477117584934
  3. Osthus RC, Karim B, Prescott JE, Smith BD, McDevitt M, Huso DL, Dang CV. The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res. 2005; 65(13): 5620-5627.10.1158/0008-5472.CAN-05-0536122473415994934
  4. Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrózek K, Bloomfield CD, Beverloo HB, Michaux L, Dastugue N, Herens C, Yigit N, De Paepe A, Hagemeijer A, Speleman F. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood. 2004; 103(1): 229-235.10.1182/blood-2003-06-216312946992
  5. Andersen MK, Christiansen DH, Pedersen-Bjergaard J. Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML. Leukemia. 2005; 19(2): 197-200.10.1038/sj.leu.240361215618958
  6. Mauvieux L, Helias C, Perrusson N, Lioure B, Sorel N, Brizard F, Lessard M. ETV6 (TEL) gene amplification in a myelodysplastic syndrome with excess of blasts. Leukemia. 2004; 18(8): 1436-1438.10.1038/sj.leu.240340315175627
  7. Rayeroux KC, Campbell LJ. Gene amplification in myeloid leukemias elucidated by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2009; 193(1): 44-5310.1016/j.cancergencyto.2009.04.00619602463
  8. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, Eaton K, Lu J, Grimes HL, Chen J, Rowley JD, Zeleznik-Le NJ. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 2009; 113(14): 3314-3322.10.1182/blood-2008-04-154310266589619188669
  9. Popescu NC, Zimonjic DB. Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med. 2002; 6(2): 151-159.10.1111/j.1582-4934.2002.tb00183.x674013512169201
  10. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12): 976-990.10.1038/nrc223119029958
  11. Farag SS, Archerd KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, Morre JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002, 21(5): 1041-1051.10.3892/ijo.21.5.1041
  12. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009; 385: 385-395.10.1182/asheducation-2009.1.385
  13. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PRK, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100(13): 4325-4336.10.1182/blood-2002-03-0772
  14. Wolman SR, Gundacker H, Appelbaum FR, Slovak ML. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2002; 100(1): 29-35.10.1182/blood.V100.1.29
  15. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004, 18(2): 115-136.10.1016/S0268-960X(03)00040-7
  16. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23): 3505-3510.10.1200/JCO.2006.08.569617687155
  17. Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol. 2006; 24(24): 3887-3894.10.1200/JCO.2005.04.545016864856
  18. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002; 16(1): 53-59.10.1038/sj.leu.240232911840263
  19. International System for Human Cytogenetic Nomenclature (2009). Shaffer LG, Slovak ML, Campbell LJ, Eds. Basel: S. Karger, 2009.
  20. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de La Chapelle A, Krahe R. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA. 2001; 98(3): 1124-1129.10.1073/pnas.98.3.11241471911158605
  21. Schoch C, Kohlmann A, Dugas M, Kern W, Hiddemann W, Schnittger S, Haferlach T. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia. 2005; 19(7): 1224-1228.10.1038/sj.leu.240381015902281
  22. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, Sloand EM, Young NS. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities Blood. 2004; 104(13): 4210-4218.10.1182/blood-2004-01-0103
  23. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005; 106(7): 2452-2461.10.1182/blood-2005-02-0734
  24. Jain AN, Chin K, Borresen-Dale A-L, Erikstein BK, Lonning PE, Kaaresen R, Gray JW. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci USA. 2001; 98(14): 7952-7957.10.1073/pnas.151241198
  25. Strout MP, Lorsbach RB, Shearer P, Sandlund JT, Raimondi SC. Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia. Leukemia. 2000; 14(7): 1314-1315.10.1038/sj.leu.2401782
  26. Jennings BA, Mills KI. C-MYC locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res. 1998; 22(10): 899-903.10.1016/S0145-2126(98)00097-6
  27. Slovak ML, Ho JP, Pettenati MJ, Khan A, Douer D, Lal S, Traweek ST. Localization of amplified MYC gene sequences of double minute chromosomes in acute myelogenous leukemia. Genes Chromosomes Cancer. 1994; 9(1): 62-67.10.1002/gcc.2870090111
  28. Storlazzi CT, Fioretos T, Paulsson K, Strömbeck B, Lassen C, Ahlgren T, Juliusson G, Mitelman F, Johansson RM. Identification of a commonly amplified 4.4 Mb region with overexpression of C8FW, but not MYC and MYC-containing double minutes in myeloid malignancies. Hum Mol Genet. 2004; 13(14): 1479-1485.10.1093/hmg/ddh164
  29. Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD. The MLL partial tandem duplication: evidence for recessice gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for moleculartargeted therapy. Blood. 2005; 106(1); 345-352.10.1182/blood-2005-01-0204
  30. Tyybäkinoja A, Saarinen-Pihkala U, Elonen E, Knuutila S. Amplified, lost and fused genes in 11q23-25 amplicon in acute myeloid leukemia, an array-CGH study. Genes Chromosomes Cancer. 2006; 45(3): 258-264.10.1002/gcc.20288
  31. Michaux L, Wlodarska I, Stul M, Dierlamm J, Mugneret F, Herens C, Beverloo B, Verhest A, Verellen-Dumoulin C, Verhoef G, Selleslag D, Madoe V, Lecomte M, DeprijckB, Ferrant A, Delannoy A, Marichal S, Duhem C, Dicato M, Hagemeiher A. MLL Amplification in myeoloid leukemias: a study of 14 cases with multiple copies of 11q23. Genes Chromosomes Cancer. 2000; 29(1): 40-47.10.1002/1098-2264(2000)9999:9999<;::AID-GCC1003>3.0.CO;2-U
Language: English
Page range: 17 - 24
Published on: Dec 8, 2011
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2011 S Angelova, M Jordanova, B Spassov, V Shivarov, M Simeonova, I Christov, P Angelova, K Alexandrova, A Stoimenov, V Nikolova, I Dimova, P Ganeva, N Tzvetkov, E Hadjiev, S Toshkov, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons License.

Volume 14 (2011): Issue 2 (December 2011)